Medical network - on March 8, 2017 new varieties most health care medicine directory as listed in the innovation between medicine in recent years, and is used in the treatment of heavy mental disease, diabetes and other major diseases of the commonly used drugs, at the same time added 91 types of children. In the new health insurance directory adjustment, fosun medicine, the sea is pharmaceutical has seven western medicine for new varieties, hengrui pharmaceutical has six, five Chinese bio-pharmaceutical. The following part of the high attention of domestic listed companies new into medical insurance directory varieties of western medicine market performance is analyzed. 

 

Hengrui pharmaceutical 

 

Hengrui pharmaceutical representatives of domestic pharmaceutical enterprise innovation, in 2017 of new varieties in the health care medicine directory has six products, respectively is right the microphones, the cloth company him, iresearch yesterday cloth, doxycycline, sulfonated liver decyl sodium, mp.the vitamine d3. The iresearch yesterday cloth is exclusive varieties, sulfonated liver decyl sodium, mp.the calciferol is domestic first imitation medicine, is now in the examination and approval. 

 

Iresearch yesterday cloth 

 

 

 

Iresearch yesterday cloth is a kind of non-steroidal anti-inflammatory analgesic drugs (NSAIDs), belongs to the highly selective cox-2 inhibitors, went public in 2011, Pfizer is patent medicine celecoxib "me too" drugs, have been closely watched. At present, the main yesterday cloth drugs mainly celecoxib, Paris yesterday cloth, relying on the test yesterday (also known as relying on yesterday cloth), iresearch smoothie, iresearch yesterday in yesterday cloth drugs market share is low, there are still a lot of room to grow in the future. 

 

 

 

Beauty's microphones set right 

 

Beauty's microphones set right belongs to the spirit of a tranquilizer. Hengrui pharmaceutical right beautiful Joe in 2013-2015 mi set injection consecutive domestic beauty right supporting mi more than 90% of market share, to our country right beautiful mi decide the market play a leading role. 

 

The Chinese biopharmaceutical 

 

Chinese bio-pharmaceutical a total of five varieties into the new health insurance directory, respectively is imatinib, hydrochlorothiazide, he sand for sand for ester, ogilvy & mather, mig column nai. 

 

He sand hydrochlorothiazide 

 

 

 

He sand jotham hydrochlorothiazide for angiotensin Ⅱ receptor antagonist and thiazide diuretics compound preparations, used in the treatment of unilateral temple he sand or hydrochlorothiazide cannot effectively control blood pressure of patients. Based on the kang, according to data from the CMH 2015 varieties of the domestic market sales of about 2.028 billion yuan, increased by 32.7%. He sha Tanzania hydrochlorothiazide originally developed by sanofi drugs, many domestic manufacturers, mainly include the board, the weather is fine and pharmaceutical, huahai pharmaceutical industry, etc., including board market share of 31.35% in 2015, the weather is fine slightly advantage relative to other domestic manufacturer. 

 

For the sand for 

 

For the sand for is mainly used for first-line therapy for the treatment of chronic leukaemia of sex of grain. At present domestic for sand for manufacturers only two bristol-myers squibb and zhengda shine. Bristol-myers squibb is for sand for the original manufacturer in 2015 for sand for 83.03% of the market, and the board is the first manufacturer, the weather is fine for this time of sand into the new medical insurance directory, in the end how markets, is affected by multiple factors such as health bidding, patients. 

 

China resources double crane 

 

China resources double crane has two new varieties of products for health insurance directory, respectively is horse cutting statin and exclusive varieties had made Sue. Horse cutting cholesterol-lowering statin belongs to medicine. China resources double crane in horse cutting statin market 37% market share, larger competitors only Japanese period. 

 

 

 

Lung surfactant 

 

 

 

For injection bovine pulmonary surfactant (cosette made Sue), used in the treatment of neonatal respiratory distress syndrome (RDS), and to prevent premature infant respiratory distress syndrome, CRC double crane is in the field of pediatric exclusive star products. The size of the market in 2015 year-on-year growth of 33% in 2014, had made Sue listed changed the neonatal respiratory failure emergency rely on imported drugs firm Sue (pig lung phospholipids injection), less dosage and treatment, the price is cheap. 

 

Shiyao group 

 

Shiyao group in the new version of health care for varieties are polyethylene glycol recombinant human granulocyte stimulating factor, butyl phthalide and sodium chloride injection. 

 

Butyl phthalide and sodium chloride injection 

 

 

 

2015 butyl phthalide drug market size exceeds 1 billion yuan, with soft capsule accounted for 88.7% of the market, injection occupied 11.3% of the size of the market. Shiyao group of butyl phthalide soft capsule (grace will prachanda) went public in 2004, for the treatment of mild and moderate acute ischemic cerebral apoplexy, is China's accession to the WTO after the first with independent intellectual property rights of innovative medicine, was listed in 2010 edition of "China's guidelines of diagnosis and treatment of acute ischemic stroke" first-line treatment drugs. Grace will not included in the health care before, its domestic sales have been not ideal, it was not until 2009 was incorporated into health care medicine directory, after sales started to grow rapidly. Injection dosage form approved in 2010, the late supplemented into six provincial health care. Now entered the 2017 medicare catalog, is expected to further drive butyl phthalide market growth. 

 

Group method 

 

Ai oprah azole 

 

Ai oprah azole enteric-coated metformin hydrochloride (one lian) is a method of exclusive varieties, previously entered the supplemented directory of 13 provinces, and entered the 2017 medicare drug directory, sales are expected to have increased significantly, moreover, have been incorporated into the moxa tripura azole sodium for injection priority review, is expected to be in the first half of the year, after the injection dosage forms listed will enrich the original market. In gastric proton pump inhibitor omeprazole in other similar products, panxi tora azole, sola azole such as annual sales are more than 1 billion to 10 billion levels, under the double positive opportunities, ai oprah azole is expected to become the next level of blockbuster 1 billion varieties? 

 

Beida pharmaceutical co. 

 

Ek for, 

 

 

 

For ek, hydrochloride is China's first with independent intellectual property rights in the treatment of lung cancer targeted anti-tumor drugs, is the core of beida pharmaceutical product returns, accounts for more than 98% of the company's main business income. The treatment for ek and (Yi Rui sand) through drug negotiate lower drug prices last year into 2017 health insurance directory, and it chooses, withdrew from the talks. Are now commonly used therapeutic agents in the treatment of EGFR mutations in non-small cell lung cancer, is expected to join health care products sales will be an advantage, market pattern will change. 

 

East sun medicine 

 

oseltamivir 

 

Oseltamivir for adults and children over 1 year old and 1 year old influenza a and b in the treatment. In 2015 the domestic market of oseltamivir scale up to 3 billion yuan. In oseltamivir GeChang home, east sun medicine "to" capsules and granules 93% market share. Medical insurance directory into varieties of oseltamivir (limited has a specific diagnosis of swine flu and for the treatment of patients with severe), is very beneficial to east sun medicine, east sun medicine has the advantage of exclusive particles formulations, self API to reduce costs, is now actively expanding its against influenza virus in pediatric market sales. 

 

The cisco 

 

DORA SiQiong 

 

The cisco's exclusive varieties mesylate DORA SiQiong is the only safe for children's tumor radiation and chemotherapy anti-nausea drugs, joining the 2017 medicare catalog and limit of radiation and chemotherapy in patients with dysphagia second-line drugs. DORA SiQiong is a selective serotonin (5 - HT1) receptor antagonist, the effect is similar to the Dan SiQiong and gamla SiQiong. In 2015, sales year-on-year growth of 22.5% in 2014. 

 

After eight years of medical insurance directory finally finished adjustment, there are multiple market expectations of higher varieties such as hengrui iresearch yesterday cloth, beida for ek, etc. For varieties into health care medicine catalogue, whether to increased sales, and sales and profits whether can is proportional to the, still need to wait for the medicare payment standards. For drug firms, also need to measure between sales and prices.